HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Bellerophon Therapeutics (NASDAQ:BLPH) but lowers the price target from $30 to $2.
June 06, 2023 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Bellerophon Therapeutics (NASDAQ:BLPH) but lowers the price target from $30 to $2.
The news of HC Wainwright & Co. maintaining a Buy rating on Bellerophon Therapeutics is positive for the stock. However, the significant reduction in the price target from $30 to $2 may create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100